国家医保局：开展医保经办全流程智能审核试点工作 11月6日，国家医疗保障局办公室关于开展医保经办全流程智能审核试点工作的通知。通知指出，整合 智能审核系统功能建设、推进人工智能技术在经办审核工作中应用，探索开发经办智能审核知识库、规 则库、模型库，建立全国通用型知识、规则与模型，推进各地审核标准与流程统一。总结推广可复制、 可借鉴的经验、标准和模式，同步建立"地方探索创新、国家评估推广"的创新应用新模式，切实提升全 国医保经办审核能力，推动基金安全关口前置，实现医保基金安全、高效、可持续运行。 重庆：打造"人工智能+制药"公共服务平台构建医药"产业大脑+未来工厂"新模式 11月6日，重庆市人民政府办公厅印发《重庆市全链条支持创新药高质量发展若干措施》，其中提出， 促进人工智能赋能药物创新。用好病理、肿瘤等数据资源，开展规范化标注与标准化处理，建设高质量 生物医药行业数据集和可信数据空间，推动医疗健康数据、临床试验信息、生物样本数据等资源安全有 序共享。加大人工智能在新药研发领域的应用，在靶点发现、分子生成、中试验证、临床试验、数字化 生产与智慧监管等环节开发智能体和应用场景，构建覆盖全链条、自主可控的人工智能 ...

Corporate Announcements - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, with Zhang holding 147,100 shares of A-shares [4] - Jiangbolong reported that its self-developed main control chip deployment exceeded 100 million units by the end of Q3, with ongoing rapid growth [5] - Asia-Pacific Pharmaceutical received a notice of disapproval for the consistency evaluation application of Diltiazem Hydrochloride Tablets, which will not significantly impact current performance [6] - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, marking the third successful inspection, enhancing its qualification for international market supply [7] - Biaobang Co. terminated its control change planning due to failure to reach consensus on core terms, leading to stock resumption [8] - Jingjin Equipment announced the release of its actual controller and chairman from detention, allowing normal operations [9] - Sand Membrane reported that part of its fundraising account was frozen, amounting to 11.74 million yuan, related to a contract dispute [10] - Renfu Pharmaceutical's subsidiary received approval for clinical trials of HWH217 tablets for treating pulmonary arterial hypertension [12] - Wanye Enterprises will change its stock name to "Xian Dao Ji Dian" effective November 12 [13] - Huahai Pharmaceutical's subsidiary passed the FDA inspection, ensuring compliance with international standards [14] Performance Metrics - Daqin Railway reported a cargo transport volume of 32.51 million tons in October, a decrease of 4.7% year-on-year [19] - Jingji Agriculture announced sales of 233,300 pigs in October, generating revenue of 317 million yuan [20] - Baiyun Airport reported a passenger throughput of 7.64 million in October, a year-on-year increase of 12.04% [21] - Dongfeng Motor's total vehicle production decreased by 23.4% year-on-year in October, with significant declines in commercial vehicle categories [22] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October [23][24] Shareholding Changes - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [25] - Tonghua Dongbao conducted its first share buyback, acquiring 0.01% of its shares for 1.29 million yuan [26] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [27] - Xili Technology announced multiple shareholders plan to reduce their stakes [28] Major Contracts - Dayu Water announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [29] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [30] - Longjian Co. won a bid for a 441 million yuan project for road construction in Heilongjiang [31] - Chongqing Construction's subsidiary won a bid for a 781 million yuan project in Chongqing [32]

（文章来源：证券日报） 证券日报网讯 11月6日晚间，人福医药发布公告称，公司全资子公司湖北生物医药产业技术研究院有限 公司近日收到国家药品监督管理局核准签发的HWH217片的《药物临床试验批准通知书》。 ...

Corporate Governance - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, effective immediately [3] - Jiang Guiting, the actual controller and chairman of Jingjin Equipment, has had his detention lifted, allowing him to resume his duties [8] - Biao Bang Co. has terminated its plans for a change in control, with stock resuming trading [7] Industry Developments - Jiangbolong reported that its self-developed main control chip deployment has exceeded 100 million units, with rapid growth expected [4] - Asia Pacific Pharmaceutical received a notice of disapproval for its consistency evaluation application for a drug, which will not significantly impact its current performance [5] - Fuxiang Pharmaceutical successfully passed a cGMP inspection by the FDA, marking its third successful inspection [6] - Huahai Pharmaceutical's subsidiary passed an FDA inspection, enhancing its international market capabilities [13] Financial Performance - Daqin Railway reported a cargo transport volume of 32.51 million tons in October 2025, a year-on-year decrease of 4.7% [18] - Jingji Zhino achieved sales revenue of 317 million yuan from selling 233,300 pigs in October 2025 [19] - Baiyun Airport reported a passenger throughput of 7.64 million in October 2025, a year-on-year increase of 12.04% [20] - Dongfeng Motor's total vehicle production in October 2025 was 6,536 units, a year-on-year decrease of 23.40% [21] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October 2025 [22] Shareholder Actions - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [24] - Tonghua Dongbao conducted its first share buyback, acquiring 143,500 shares for 1.29 million yuan [25] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [26] Project Wins - Dayu Water-saving announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [28] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [29] - Longjian Co. won a project bid worth 441 million yuan for road construction in Heilongjiang [30] - Chongqing Construction's subsidiary won a project bid worth 781 million yuan for a residential project in Chongqing [31]

HWH217 片为化学药品 2.3 类含有已知活性成分的新复方制剂，拟用于治疗（WHO 第 1 组）动脉性肺 动脉高压。经Insight数据库统计，目前国内尚无复方制剂产品获批上市用于该适应症的治疗。截至目前 该项目累计研发投入约为600万元人民币。 根据《中华人民共和国药品管理法》有关规定，经审查，2025年8月15日受理的HWH217片临床试验申 请符合药品注册的有关要求，同意本品开展"用于治疗（WHO第1组）动脉性肺动脉高压"的临床试验。 格隆汇11月6日丨人福医药（维权）(600079.SH)公布，公司全资子公司湖北生物医药产业技术研究院有 限公司近日收到国家药品监督管理局核准签发的HWH217片的《药物临床试验批准通知书》。药品名 称：HWH217片，注册分类：化学药品2.3类。 ...

格隆汇11月6日｜人福医药（维权）(600079.SH)公告称，全资子公司湖北生物医药产业技术研究院有限 公司近日收到国家药品监督管理局核准签发的HWH217片的《药物临床试验批准通知书》。HWH217片 为化学药品2.3类含有已知活性成分的新复方制剂，拟用于治疗（WHO第1组）动脉性肺动脉高压。经 Insight数据库统计，目前国内尚无复方制剂产品获批上市用于该适应症的治疗。截至目前该项目累计研 发投入约为600万元。 ...